---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-039797"
form_type: "8-K"
ticker: "ATRA"
cik: "0001604464"
company_name: "Atara Biotherapeutics, Inc."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T02:04:00.783164+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Atara Q2 net loss $71.1M; IND cleared for ATA3219; tab-cel BLA meeting scheduled

## Summary
- Net loss of $71.1M ($0.68 per share) vs net income of $18.5M ($0.18) in Q2 2022, which included one-time gains.
- Cash, equivalents and investments $153.6M as of June 30, 2023; expected runway into Q2 2024 (net cash used in ops $52.8M in Q2).
- IND cleared for allogeneic CAR T ATA3219 in relapsed/refractory B-cell NHL; Phase 1 to start in coming months.
- FDA meeting scheduled to resolve comparability for tab-cel (EBVALLO) BLA submission; commercial discussions advancing.
- Primary analysis of ATA188 Phase 2 EMBOLD study in progressive MS to be communicated in early November with data from >90 patients.

## SEC filing metadata
- accession: 0000950170-23-039797
- form_type: 8-K
- ticker: ATRA
- cik: 0001604464
- company_name: Atara Biotherapeutics, Inc.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604464/000095017023039797/0000950170-23-039797-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604464/000095017023039797/atra-20230808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-039797
- JSON: https://secwatch.observer/filing/0000950170-23-039797.json
- Plain text: https://secwatch.observer/filing/0000950170-23-039797.txt

## Key facts
- Earnings Releases
  Atara Biotherapeutics, Inc. reported second quarter ended June 30, 2023 results: net income net loss of $71.1 million, or $0.68 per share for the second quarter 2023.
  - Period: second quarter ended June 30, 2023
  - Net income: net loss of $71.1 million, or $0.68 per share for the second quarter 2023
  - Result: reported results
  source text: Atara reported a net loss of $71.1 million, or $0.68 per share for the second quarter 2023, as compared to net income of $18.5 million, or $0.18 per share for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604464/000095017023039797/0000950170-23-039797-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.